NeoGenomics, Inc. reaffirmed consolidated earnings guidance for the full year 2024. For the year, the company expects consolidated revenue of $650 million to $660 million and net loss of $72 million to $66 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.8 USD | -1.20% | -6.15% | -8.53% |
May. 02 | North American Morning Briefing : Stock Futures -3- | DJ |
Apr. 30 | Needham Lowers Price Target on NeoGenomics to $19 From $24 Due to Peer Multiple Compression, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.53% | 1.89B | |
-17.05% | 8.55B | |
+65.23% | 4.24B | |
-1.63% | 2.53B | |
-9.81% | 2.44B | |
-41.76% | 2.35B | |
-19.29% | 1.55B | |
-39.61% | 1.23B | |
+9.68% | 1.13B | |
+19.57% | 994M |
- Stock Market
- Equities
- NEO Stock
- News NeoGenomics, Inc.
- NeoGenomics, Inc. Reaffirms Consolidated Earnings Guidance for the Full Year 2024